Skip to main content
SpringerLink
Log in

Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Heart failure (HF) affects approximately 5.1 million adults in the USA, with expectations of a rise to nearly 8 million adults by 2030. Patients with HF are at increased risk for morbidity/mortality, and comorbidities can further complicate care for these patients. Diabetes mellitus, chronic pain, arrhythmias, and depression are diagnoses that often coexist with HF. Medications commonly used to treat these comorbidities may induce or worsen HF symptoms, so determining appropriate drug therapy is important. Healthcare providers must understand the relationship between these medications and HF in order to improve prescribing practices to increase patient safety and reduce morbidity and mortality. This manuscript discusses the association between certain medications used to treat the aforementioned diagnoses and their relationship to HF. The purpose of this article is to provide guidance on which pharmacologic options require special consideration, increased monitoring, or complete avoidance in HF patients with diabetes mellitus, chronic pain, arrhythmias, and/or depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJV, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62(16):e147–239.

    Article  PubMed  Google Scholar 

  3. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.

    Article  PubMed  Google Scholar 

  4. Havranek ED, Masoudi FA, Westfall KA, et al. Spectrum of heart failure in older patients: results from the National Heart Failure Project. Am Heart J. 2002;143:412–7.

    Article  PubMed  Google Scholar 

  5. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Atlanta: U.S. Department of Health and Human Services; 2014.

    Google Scholar 

  6. Nichols G, Gullion C, Koro C, et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care. 2004;27(8):1879–84.

    Article  PubMed  Google Scholar 

  7. Go A, Mozaffarian D, Roger V, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2013;129:e28–292.

    Article  PubMed  Google Scholar 

  8. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 26 June 2014.

  9. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S14–80.

    Article  Google Scholar 

  10. Misbin R, Green L, Stadel B, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338(4):265–6.

    Article  CAS  PubMed  Google Scholar 

  11. Inzucchi S. Metformin and heart failure: innocent until proven guilty. Diabetes Care. 2005;28(10):2585–7.

    Article  PubMed  Google Scholar 

  12. Masoudi F, Inzucchi S, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. Circulation. 2005;111:583–90.

    Article  CAS  PubMed  Google Scholar 

  13. Eurich D, Majumdar S, McAlister F, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–51.

    Article  CAS  PubMed  Google Scholar 

  14. Inzucchi S, Masoudi F, McGuire D. Metformin in heart failure. Diabetes Care. 2007;30(12):e129.

    Article  PubMed  Google Scholar 

  15. Glucophage (metformin) (package insert). Princeton: Bristol-Myers Squibb; 2009.

  16. Eurich D, Weir D, Majumdar S, et al. Comparative safety and effectiveness of metformin in patients with diabetes and heart failure: systematic review of observational studies involving 3400 patients. Circ Heart Failure. 2013;6(3):395–402.

    Article  CAS  Google Scholar 

  17. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41(4):642–6.

    Article  CAS  PubMed  Google Scholar 

  18. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4(1):53–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Andersson C, Oleson J, Hansen P, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–53.

    Article  CAS  PubMed  Google Scholar 

  20. PL Detail-Document, Clinical Use of Metformin in Special Populations. Pharmacist’s Letter/Prescriber’s Letter. March 2015.

  21. Lipska K, Bailey C, Inzucchi S. Use of metformin the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Avandia (rosiglitazone) (package insert). Deerfield: GlaxoSmithKline; 2013.

  23. Actos (pioglitazone) (package insert). Research Triangle Park: Takeda; 2014.

  24. Guan Y, Hao C, Cha D, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861–6.

    Article  CAS  PubMed  Google Scholar 

  25. Nesto R, Bell D, Bonow R, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–8.

    Article  PubMed  Google Scholar 

  26. Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial IN macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–89.

    Article  CAS  PubMed  Google Scholar 

  27. Lago R, Singh P, Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–36.

    Article  CAS  PubMed  Google Scholar 

  28. Giles T, Miller A, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled trial in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14:445–52.

    Article  CAS  PubMed  Google Scholar 

  29. Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet. 2009;373:2125–35.

    Article  CAS  PubMed  Google Scholar 

  30. Hernandez A, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115–28.

    Article  CAS  PubMed  Google Scholar 

  31. Gooßen K, Graber S. Long-term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061–72.

    PubMed  Google Scholar 

  32. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32:147–58.

    Article  CAS  PubMed  Google Scholar 

  33. Scirica B, Bhatt D, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

    Article  CAS  PubMed  Google Scholar 

  34. White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.

    Article  CAS  PubMed  Google Scholar 

  35. Zannad F, Cannon C, Cushman W, et al. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients. J Am Coll Cardiol 2014;63(12_S). doi:10.1016/S0735-1097(14)60117-0.

  36. Weir D, McAlister F, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–82.

    Article  PubMed  Google Scholar 

  37. Kannan S, Torricelli S, Pantalone K, et al. The risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from Cleveland Clinic. Abstract presented at: 2014 Joint Meeting of the International Society of Endocrinology and the Endocrine Society; June 23. Chicago; 2014.

  38. Kim S, Glynn R, Liu J, et al. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a population-based cohort study. Abstract presented at: 2014 Joint Meeting of the International Society of Endocrinology and the Endocrine Society: June 23. Chicago; 2014.

  39. Nainggolan L. DPP-4 inhibitors and heart failure in diabetes: be vigilant. Medscape Medical News. 2013. http://www.medscape.com/viewarticle/817543#1. Accessed 26 June 2014.

  40. Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press; 2011.

  41. Evangelista LS, Sackett E, Dracup K. Pain and heart failure: unrecognized and untreated. Eur J Cardiovas Nurs. 2009;8(3):169–73.

    Article  Google Scholar 

  42. Godfrey C, Harrison MB, Medves J, et al. The symptom of pain with heart failure: A systematic review. J Cardiac Failure. 2006;12(4):307–13.

    Article  Google Scholar 

  43. Patrono C, Baigent BM. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129:907–16.

    Article  PubMed  Google Scholar 

  44. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDS associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158(10):1108–12.

    Article  CAS  PubMed  Google Scholar 

  45. Dzau VJ, Packer M, Silly LS, et al. Prostaglandins in severe congestive heart failure—relation to activation of the renin–angiotensin system and hyponatremia. N Engl J Med. 1984;310:347–52.

    Article  CAS  PubMed  Google Scholar 

  46. Page J, Henry D. Consumption of NSAIDS and the development of congestive heart failure in elderly patients. Arch Intern Med. 2000;160:777–84.

    Article  CAS  PubMed  Google Scholar 

  47. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14:240–6.

    PubMed  Google Scholar 

  48. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–6.

    Article  CAS  PubMed  Google Scholar 

  49. Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007;57(3):516–23.

    Article  CAS  PubMed  Google Scholar 

  50. McGettigan P, Han P, Jones L, et al. Selective cox-2 inhibitors, NSAIDS and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol. 2008;65(6):927–34.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Coxibs and Traditional NSAID Trialists’ (CNT) Collarboration. Vascular and upper gastrointestinal Effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382:769-779.

  52. Ho JM, Tricco AC, Perrier L, et al. Risk of heart failure and edema associated with the use of pregabalin: a systematic review. Syst Rev. 2013;2(25):1–5.

    Google Scholar 

  53. Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826–36.

    Article  CAS  PubMed  Google Scholar 

  54. Lyrica (gabapentin) (package insert). New York: Pfizer; 2013.

  55. Spadotto V, Zorzi A, ElMaghawry M, et al. Heart failure due to ‘stress cardiomyopathy’: a severe manifestation of opioid withdrawal syndrome. Eur Heart J Acute Cardiovas Care. 2013;2(1):84–7.

    Article  Google Scholar 

  56. Lemesle F, Lemesle F, Nicola W. First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction. Am J Emerg Med. 2010;28:387.

    Article  PubMed  Google Scholar 

  57. Saiful FB, Lafferty J, Jun CH, et al. Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. Rev Cardiovasc Med. 2011;12:164–7.

    Article  PubMed  Google Scholar 

  58. Haanpaa ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010;85(3)(suppl):S15–S25.

  59. Justo D, Gal-Oz A, Paran Y, et al. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101:133–8.

    Article  Google Scholar 

  60. Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Inter Med. 1996;156:1047.

    Article  CAS  Google Scholar 

  61. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237.

    Article  CAS  PubMed  Google Scholar 

  62. Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: Premise and promise. Curr Neuropharmacol 2009;7(4):331–336.

  63. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin. 2007;23(1):175–84.

    Article  CAS  PubMed  Google Scholar 

  64. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437–55.

    Article  CAS  PubMed  Google Scholar 

  65. Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. Ann Pharmacother. 2004;38(12):2078–85.

    Article  CAS  PubMed  Google Scholar 

  66. Tyler D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide, and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013;3(3):151–61.

    Article  Google Scholar 

  67. Cymbalta (duloxetine) (package insert). Indianapolis: Lily; 2004.

  68. Effexor XR (venlafaxine) (package insert). New York: Pfizer; 2014.

  69. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53(Suppl 7):26–33.

    Article  CAS  PubMed  Google Scholar 

  70. Megarbane B, Leprince P, Deye N, et al. Extracorporeal life support in a case of acute carbamazepine poisoning with life-threatening refractory myocardial failure. Intensive Care Med. 2006;32:1409–13.

    Article  PubMed  Google Scholar 

  71. Faisy C, Guerot E, Diehl JL, et al. Carbamazepine associated severe left ventricular dysfunction. J Toxicol Clin Toxicol. 2007;38:339–42.

    Article  Google Scholar 

  72. Terrance CF, Fromm G. Congestive heart failure during carbamazepine therapy. Ann Neurol. 1980;8(2):200–1.

    Article  Google Scholar 

  73. Tegretol (carbamazepine) (package insert). East Hanover: Novartis; 2014.

  74. Marini AM, Choi JY, Labutta RJ. Transient neurological deficits associated with carbamazepine-induced hypertension. Clin Neuropharmacol. 2003;26(4):174–6.

    Article  CAS  PubMed  Google Scholar 

  75. Trileptal (Package Insert). East Hanover: Novartis; 2011.

  76. January CT, Wann S, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2014. doi:10.1016/j.jacc.2014.03.022.

    PubMed  Google Scholar 

  77. Poole-Wilson PA, Swedberg K, Clelan JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): Randomized controlled trial. Lancet 2003; 362:7–13.

  78. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: metoprolol cr/xL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.

    Article  Google Scholar 

  79. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II). Lancet. 1999;353:9–13.

    Article  Google Scholar 

  80. Swedberg K, Olsson LH, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur H J. 2005;26:1303–8.

    Article  CAS  Google Scholar 

  81. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498–501.

    Article  CAS  PubMed  Google Scholar 

  82. Van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure: experiences from the MERIT-HF Study. Eur J Heart Fail. 2006;8:539–46.

    Article  PubMed  Google Scholar 

  83. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–33.

    Article  CAS  PubMed  Google Scholar 

  84. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014. doi:10.1016/S0140-6736(14)61373-8.

    PubMed  Google Scholar 

  85. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441–6.

    Article  CAS  PubMed  Google Scholar 

  86. Sturm B, Pacher R, Strametz-Juranek J, et al. Effect of β1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail. 2000;2:407–12.

    Article  CAS  PubMed  Google Scholar 

  87. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–67.

    Article  Google Scholar 

  88. Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15:324–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Flather MD, Shibata MC, Coasts AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur H J. 2005;26:215–25.

    Article  CAS  Google Scholar 

  90. Mulder BA, van Veldhuisen DJ, Crijns HJ, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14:1171–8.

    Article  CAS  PubMed  Google Scholar 

  91. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  92. Meyer P, White M, Muhib M, et al. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol. 2008;102:1681–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Norpace (disopyramide phosphate) [package insert]. Chicago, IL: Searle LLC; 2006.

  94. Quinidine gluconate (package insert). Richmond: Richmond Pharmaceuticals, Inc; 2011.

  95. The Cardiac Arrhythmia Suppression Trial Investigators. Effects of encainide and flecainide of mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12.

    Article  Google Scholar 

  96. The Cardiac Arrhythmia Suppression Trial Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227–33.

    Article  Google Scholar 

  97. Cordarone (amiodarone) (package insert). Philadelphia: Wyeth Laboratories; 2004.

  98. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77–82.

    Article  CAS  PubMed  Google Scholar 

  99. Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493–8.

    Article  CAS  PubMed  Google Scholar 

  100. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250–9.

    Article  PubMed  Google Scholar 

  101. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857–65.

    Article  CAS  PubMed  Google Scholar 

  102. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation. 2001;104:292–6.

    Article  CAS  PubMed  Google Scholar 

  103. Tikosyn (dofetilide) (package insert). New York: Pfizer; 2011.

  104. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left-ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12.

    Article  CAS  PubMed  Google Scholar 

  105. Multaq (dronedarone) (package insert). Bridgewater: Sanofi-aventis; 2014.

  106. Kober L, Torp-Pederson C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.

    Article  PubMed  Google Scholar 

  107. Hohnloser SH, Crijns HJGM, van Eickels, M, et al., for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668–678.

  108. Rutledge T, Reis V, Linke S, et al. Depression in heart failure: a meta-analytic review of prevalence, intervention effects and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.

    Article  PubMed  Google Scholar 

  109. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175–89.

    Article  PubMed  Google Scholar 

  110. Cully J, Jimenez D, Ledoux T, Deswal A. Recognition and treatment of depression and anxiety symptoms in heart failure. J Clin Psychiatry. 2009;11(3):103–9.

    Google Scholar 

  111. Feinstein R, Blumenfield M, Orlowski B, et al. A national survey of cardiovascular physicians’ beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev. 2006;14(4):164–9.

    Article  PubMed  Google Scholar 

  112. Huffman JC, Smith FA, Blais MA, et al. Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. Am J Cardiol. 2006;98(3):319–24.

    Article  PubMed  Google Scholar 

  113. Lichtman J, Bigger T, Blumenthal J, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment—a science advisory from the American Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research. Circulation. 2008;118:1768–75.

    Article  PubMed  Google Scholar 

  114. Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32:509–15.

    Article  Google Scholar 

  115. Pfizer. Welcome to the Patient Health Questionnaire (PHQ) Screeners. http://www.phqscreeners.com. Accessed 20 Feb 2015.

  116. Silver M. Depression and heart failure: an overview of what we know and don’t know. Cleve Clin J Med. 2010;77(suppl 3):S7–11.

    Article  PubMed  Google Scholar 

  117. O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF Trial. J Am Coll Cardiol. 2010;56(9):692–9.

    Article  PubMed Central  PubMed  Google Scholar 

  118. Gelenberg A, Freeman M, Markowitz J, et al. APA practice guideline for the treatment of patients with major depressive disorder, 3rd edn. American Psychiatric Association. 2010.

  119. Jiang W, O’Connor C, Silva SG, et al. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patientswith CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156:437–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  120. Gottlieb S, Kop W, Thomas S, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153:868–73.

    Article  CAS  PubMed  Google Scholar 

  121. Tousoulis D, Antoniadis C, Drolias A, et al. Selective serotonin reuptake inhibitors modify the effect of β-blockers on long-term survival of patients with end-stage heart failure and major depression. J Cardiac Fail. 2008;14:456–64.

    Article  CAS  Google Scholar 

  122. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.

    Article  CAS  PubMed  Google Scholar 

  123. van Melle JP, Verbeek DE, van den Berg MP, et al. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol. 2006;48:2209–14.

    Article  PubMed  Google Scholar 

  124. Acharya T, Acharya S, Tringali S, et al. Associations of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population. Pharmacotherapy. 2013;33(10):1053–61.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No external funding was used in the preparation of this manuscript. None of the authors have any potential conflict of interest that might be relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Pharmacy Practice, Concordia University Wisconsin School of Pharmacy, Mequon, WI, 53097, USA

    Beth DeJongh

  2. Clinical Pharmacy Services, Cedars Sinai Health Associates, Beverly Hills, CA, 90211, USA

    Kade Birkeland

  3. VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA

    Michael Brenner

Authors
  1. Beth DeJongh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kade Birkeland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Brenner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DeJongh, B., Birkeland, K. & Brenner, M. Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm. Am J Cardiovasc Drugs 15, 171–184 (2015). https://doi.org/10.1007/s40256-015-0115-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-015-0115-6

Keywords

Search

Navigation